Moligand™, ≥96% Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Purpurogallin is a naturally phenol extracted from the plants of Quercus spp, has potent xanthine oxidase (XO) inhibitory activity with an IC 50 of 0.2 µM. Purpurogallin has antioxidant and anti-inflammatory effects
In Vitro
Purpurogallin (50 or 100 µM; 7 or 25 hours; BV2 murine microglial cells) treatment attenuates the production of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) by suppressing their mRNA and protein expression in LPS-stimulated BV2 microglial cells. Purpurogallin (100 µM; 75-120 minutes; BV2 murine microglial cells) exhibits anti-inflammatory properties by suppressing the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways in LPS-stimulated BV2 microglial cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: BV2 murine microglial cells Concentration: 50 or 100 µM Incubation Time: 7 or 25 hours Result: Attenuated the production of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) by suppressing their mRNA and protein expression. Western Blot AnalysisCell Line: BV2 murine microglial cells Concentration: 100 µM Incubation Time: 75 minutes, 90 minutes, 120 minutes Result: Suppressed the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways.
In Vivo
Purpurogallin (100-400 μg/kg; intraperitoneal injection; for 48 or 72 hours; male Sprague-Dawley rats) exerts its neuroinflammation effect through the dual effect of inhibiting IL-6 and TNF-α mRNA expression and reducing HMGB1 protein and mRNA expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Fifty-four male Sprague-Dawley rats (250-350 g) with subarachnoid hemorrhage (SAH)Dosage: 100 μg/kg, 200 μg/kg, 400 μg/kg Administration: Intraperitoneal injection; for 48 or 72 hours Result: Dose-dependently reduced HMGB1 protein expression. High dose reduced TNF-α and HMGB1 mRNA levels.
Form:Solid
IC50& Target:IC50: 0.2 µM (xanthine oxidase)
| Canonical Smiles | O=C1C(O)=CC=CC2=CC(O)=C(O)C(O)=C21 |
|---|---|
| Molecular Weight | 220.17 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 G2501635 | Certificate of Analysis | Jun 10, 2025 | P649449 |
| G2501636 | Certificate of Analysis | Jun 10, 2025 | P649449 |
| G2501637 | Certificate of Analysis | Jun 10, 2025 | P649449 |
| G2501638 | Certificate of Analysis | Jun 10, 2025 | P649449 |
| G2501639 | Certificate of Analysis | Jun 10, 2025 | P649449 |
| G2501640 | Certificate of Analysis | Jun 10, 2025 | P649449 |
| G2501641 | Certificate of Analysis | Jun 10, 2025 | P649449 |
| G2501642 | Certificate of Analysis | Jun 10, 2025 | P649449 |
| Solubility | DMSO : 100 mg/mL (454.17 mM; Need ultrasonic) |
|---|
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →
